|
|
Devices and Drugs of Tomorrow 2002: Prevention and Treatment of Coronary RestenosisPublished by: Datamonitor Published: Apr. 5, 2002 - 207 Pages Table of ContentsRestenosis DATAMONITOR HEALTHCARE Europe and Rest of World - mmeek@datamonitor.com or +44 20 7675 7311 EXECUTIVE SUMMARY Scope Datamonitor insight into the restenosis market Key metrics TABLE OF CONTENTS PATIENT POTENTIAL Definition of disease The development of restenosis Future trends in the prevalence of PCI and stenting Number of PCI procedures PCI involving stenting in the seven major markets PCI patients with diabetes Additional epidemiology data R&D APPROACH Definition of current ‘gold standard’ therapies Unmet needs in restenosis More effective prevention and treatment options for restenosis Increased availability of more cost-effective care More complete understanding of the pathology of restenosis Improved diagnosis of restenosis Clinical endpoints in restenosis trials Measurement of restenosis rate Event free survival Clinical trial design specifics RESTENOSIS PIPELINE OVERVIEW Overview of the restenosis R&D pipeline Restenosis pipeline analysis by type of therapy Breakdown by type of therapy Breakdown by phase of development Breakdown by region of develoment Pipeline analysis by company type Pipeline analysis by licensing strategy Overview of licensing strategies Key marketing opportunities DEVICE-BASED PIPELINE Classification of devices pipeline Drug-eluting and drug-coated stents Overview of developmental drug-eluting and drug-coated stents Cordis: sirolimus-eluting stent Potential strategic alliances for Cordis Will drug-eluting stents prove too costly? Cook Incorporated: paclitaxel-eluting stent Strategic alliances to maximize potential revenue Boston Scientific: paclitaxel-eluting stent SCORE trial terminated Increasing presence within the medical device market Other promising phase I drug-eluting stent programs Ultrasound therapy Overview of developmental ultrasound therapy Pharmasonics: intravascular sonotherapy treatment Recently discontinued developmental devices Guidant: Actinomycin-D-eluting stent Biocompatibles: Batimastat-coated stent Quanam Medical: paclitaxel-eluting stent DRUG-BASED PIPELINE Classification of drug therapy pipeline Drug therapy Overview of developmental drug therapies AtheroGenics: AGI-1067 Other promising developmental drug therapies Gene therapy Overview of developmental gene therapies Valentis: VEGF-165 Cardion Pharmaceuticals: NOStentin Antisense therapy Overview of developmental antisense compounds AVI BioPharma: Resten-NG Recently discontinued developmental compounds Drug therapy Antisense compounds COMPARATIVE ANALYSIS Introduction Comparative analysis of devices versus drugs Clinical development through to approval The Role of CE-Marking Medical Device Vigilance (MDV) Comparative analysis of the most promising devices and drugs Efficacy Cost Overview of likely market entry Prevention and/or treatment of restenosis Marketing strength Overall performance Conclusion THE FUTURE DECODED Forecasting methodology Calculating patient populations for different types of stents Calculating conventional stent market sizes Calculating individual drug-eluting stent brand share and sales Forecasts based on 1.5 stents per patient Coronary stent market forecasts Individual drug-eluting stent brand forecasts APPENDIX Datamonitor's Cardiovascular Business Unit Table of tables Table of figures Bibliography Clinical trial data Key conferences and associations Epidemiology methodology Number of PCI and stenting procedures Forecast methodology for prevalence of PCI and stenting References R&D research methodology Introduction Hypothesis formulation Hypothesis testing Data verification and quality control © Datamonitor 2002. All Rights Reserved. Abstract‘Devices and Drugs of Tomorrow 2002: Prevention and Treatment of Coronary Restenosis’ provides an in-depth, critical evaluation of the key device and drug-based products currently in phase I development and beyond for restenosis. The scope of this report covers the following: * drug-eluting and drug-coated stents; * ultrasound therapy; * drug therapy; * gene therapy; * antisense therapy. Analysis in this report is based on material available up to the end of March 2002, including information from the XXII Annual Congress of the European Society of Cardiology, September 2001, American Heart Association Scientific Sessions, November 2001, and the American College of Cardiology 51st Annual Scientific Session, March 2002. Analysis is supplemented by primary research conducted with opinion leaders in the field of interventional cardiology and medical equipment industry executives.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||